Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Psychiatry/Psychology

Search Medical Condition
Please enter condition
Please choose location

Schizophrenia and Schizoaffective Disorders Clinical Trials

A listing of Schizophrenia and Schizoaffective Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (172) clinical trials

A phase III study to evaluate weight gain of ALKS3831 compared to olanzapine in adults with schizophrenia

Phase

Outpatient study for an investigational medication for schizophrenia. Inclusionary Criteria: Males and females Between the ages of 18-70 Schizophrenia or Schizoaffective disorder Length of Study approx 2 month Total number of outpatient visits: 7

Phase N/A

An 8 week, placebo-controlled, double-blind, randomized, fixed-dose efficacy and safety study of asenapine in adolescent subjects with schizophrenia. Patient Inclustion Criteria: The subject is aged between 10 and 17 years, inclusive. The subject suffers from schizophrenia.

Phase

A randomized, double-blind, placebo-controlled, parallel-26 week, phase 3 study of 2 doses of an alpha-nicotinic acetylcholine receptor agonist (EVP-6124) or placebo as an adjunctive pro-cognitive treatment in schizophrenic subjects on chronic stable atypical antipsychotic therapy.

Phase
Phase N/A

Daniel Mamah, MD is conducting a research study to examine brain functional connectivity and network patterns in participants with schizophrenia or bipolar disorder. Participation includes 2 outpatient study visits that will last about 2 - 5 hours each. There will be an MRI scan and clinical assessment/interview. Possible risks and ...

Phase N/A

An adaptive, Phase IIB/III, double-blind, randomized, placebo-controlled, multi-center study of the safety and efficacy of study drug used for treatment of Schizophrenia in Adolescents

Phase N/A

The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.

Phase

A Phase II, Randomized, Double-blind Study to Evaluate Efficacy, Safety, and Tolerablity of ALKS 3831 in Subjects with Schizophrenia with Alcohol Use Disorder

Phase

The objective of the study is to investigate the efficacy, safety and tolerability of four different doses of BI 409306 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.

Phase